AstraZeneca’s cancer immunotherapy Imfinzi broke new ground when it was approved in 2018 for locally advanced non-small cell lung cancer (NSCLC) that can’t be treated with surgery and has not progressed after chemotherapy and radiation therapy (CRT), but the company’s plan to expand its use in this setting has been thwarted.
